85963-91-3

Upstream product

• 105-45-3 acetoacetic acid methyl ester 
• 21759-69-3 β-N-Methylaminocrotonic acid methyl ester 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 103231-54-5 (Z)-3-Hydroxy-2-(4-nitro-benzoyl)-but-2-enoic acid methyl ester 
• 355024-58-7 1-(2-chlorophenyl)ethyl(3-methyl-5-(4-nitrophenyl)isoxazol-4-yl)carbamate 
• 1391908-11-4 methyl 3-methyl-5-(4-nitrophenyl)isoxazole-4-carboxylate 
• 91135-88-5 3-methyl-5-(4-nitrophenyl)isoxazole-4-carboxylic acid 
• 1391908-12-5 1-(2-chlorophenyl)ethyl(5-(4-aminophenyl)-3-methylisoxazol-4-yl)carbamate 
• 1391907-61-1 1-(2-chlorophenyl)ethyl(3-methyl-5-(4-(methylsulfonamido)phenyl)isoxazol-4-yl)carbamate 

Relevant academic research and scientific papers

COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF

The present invention relates to a compound as antagonist of LPA receptor, and a pharmaceutical composition comprising the same. The present invention also relates to the use of the compound and the composition, and a method of using the compound to treat

COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF

The present invention discloses a compound as antagonist of LPA receptor, and a pharmaceutical composition comprising the same. The present invention also discloses the use of the compound and the composition, and a method of using the compound to treat, prevent or diagnose diseases, disorders or conditions associated with one or more of the LPA receptors.